Literature DB >> 15302981

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.

Giuseppe Derosa1, Pietro D Ragonesi, Amedeo Mugellini, Leonardina Ciccarelli, Roberto Fogari.   

Abstract

We evaluated the antihypertensive activity, glucose homeostasis and plasma lipid profile in patients with mild hypertension and type 2 diabetes mellitus treated by diet and exercise, and not in receipt of oral hyperglycemics, following 12-month treatment with either telmisartan or eprosartan. In this double-blind, placebo-controlled trial, 119 patients with mild essential hypertension (diastolic blood pressure [DBP] 91-104 mmHg) and type 2 diabetes were divided into three groups and randomized to receive once-daily telmisartan 40 mg, eprosartan 600 mg, or placebo for 12 months. At enrollment, patients were advised on diet (1,400-1,600 kcal/day) and exercise (physical aerobics on a bicycle for at least 30 min on 4 days each week). Compared with baseline, a significant reduction (p<0.01) in seated trough systolic blood pressure (SBP) was detected after 12-month treatment with either telmisartan or eprosartan. Seated trough DBP was also reduced by telmisartan (p<0.01) and eprosartan (p<0.05); the antihypertensive effect of telmisartan was significantly superior (p<0.05). No change in body mass index or glucose metabolism was observed with either active treatment, or with placebo. Telmisartan, but not eprosartan, significantly improved plasma total cholesterol (p<0.01), low-density lipoprotein cholesterol (p<0.01) and triglycerides (p<0.05) compared with eprosartan. In conclusion, 12-month telmisartan treatment produced a significantly greater reduction in DBP than eprosartan and significantly improved plasma lipids. The improvement could be due to varying pharmacokinetic/pharmacodynamic properties of telmisartan compared with eprosartan, even if it is not clear about the relationship between angiotensin-II receptor blockade and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302981     DOI: 10.1291/hypres.27.457

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  35 in total

Review 1.  Telmisartan: a review of its use in the management of hypertension.

Authors:  Anna J Battershill; Lesley J Scott
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients.

Authors:  R Negro; G Formoso; H Hassan
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

3.  Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials.

Authors:  Feng-Ying Xu; Bo Yang; Duo Shi; Hao Li; Zui Zou; Xue-Yin Shi
Journal:  Eur J Clin Pharmacol       Date:  2011-09-01       Impact factor: 2.953

4.  Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.

Authors:  Tony Antoniou; Ximena Camacho; Zhan Yao; Tara Gomes; David N Juurlink; Muhammad M Mamdani
Journal:  CMAJ       Date:  2013-07-08       Impact factor: 8.262

5.  Angiotensin II, hypertension and angiotensin II receptor antagonism: Roles in the behavioural and brain pathology of a mouse model of Alzheimer's disease.

Authors:  Maximilian Wiesmann; Monica Roelofs; Robert van der Lugt; Arend Heerschap; Amanda J Kiliaan; Jurgen Ahr Claassen
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

6.  Long-term effect of telmisartan on Alzheimer's amyloid genesis in SHR-SR after tMCAO.

Authors:  Tomoko Kurata; Violeta Lukic; Miki Kozuki; Daisuke Wada; Kazunori Miyazaki; Nobutoshi Morimoto; Yasuyuki Ohta; Kentaro Deguchi; Toru Yamashita; Nozomi Hishikawa; Kosuke Matsuzono; Yoshio Ikeda; Tatsushi Kamiya; Koji Abe
Journal:  Transl Stroke Res       Date:  2014-01-17       Impact factor: 6.829

Review 7.  Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system.

Authors:  Michael L Tuck
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

Review 8.  New standards in hypertension and cardiovascular risk management: focus on telmisartan.

Authors:  Domenico Galzerano; Cristina Capogrosso; Sara Di Michele; Antonio Galzerano; Paola Paparello; Diana Lama; Carlo Gaudio
Journal:  Vasc Health Risk Manag       Date:  2010-03-24

Review 9.  Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.

Authors:  David H G Smith
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Clinical profile of eprosartan: a different angiotensin II receptor blocker.

Authors:  P J Blankestijn; H Rupp
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.